期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

左西孟旦治疗难治性心力衰竭的临床价值分析 被引量：2

暂未订购
导出
摘要 目的:对左西孟旦治疗难治性心力衰竭的临床价值进行研究。方法:选择难治性心力衰竭患者54例进行研究分析,并按照治疗方法将其分为治疗组(采用左西孟旦治疗)与对照组(采用米力农治疗),每组27例,对采用不同治疗方法治疗患者的临床治疗总有效率进行对比。结果:治疗组患者采用左西孟旦治疗后,其临床治疗总有效率高达92.59%,对照组患者采用米力农治疗后,其临床治疗总有效率仅为66.67%。两组临床治疗总有效率比较差异有统计学意义(P<0.05)。结论:左西孟旦治疗难治性心力衰竭疾病临床上效果显著,促使患者早日康复。
作者 王墨茹
机构地区 山东省莱州市人民医院心内科
出处 《吉林医学》 CAS 2015年第2期236-236,共1页 Jilin Medical Journal
关键词 左西孟旦 难治性心力衰竭 临床价值
分类号 R541.6 [医药卫生—心血管疾病]
  • 相关文献

参考文献3

二级参考文献20

  • 1Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure(the LIDO study) :a randomised double-blind trial[J]. Lancet, 2002,360 (9 328) : 196.
  • 2Cleland JG, Ghosh J, Freemantle N, et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure [J]. Eur J Heart Fail, 2004,6 (4) : 501.
  • 3Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study [J]. Circulation, 2002,106 (24) :3 068.
  • 4Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of thd European Society of Cardiology[J]. Eur Heart J, 2005,26(4) :384.
  • 5Dec GW. Acute decompensated heart failure: the shrinking role of inotropic therapy [J]. JAm Coil Cardiol, 2005, 46(1):65.
  • 6Nijhawan N, Nicolosi AC, Montgomery MW, et al. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial [J]. J Cardiovasc Pharmacol, 1999, 34 (2) : 219.
  • 7Nieminen MS, Akkila J, Hasenfuss G, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure[J]. JAm Coll Cardiol,2000 ,36( 6 ) : 1 903.
  • 8Moiseyev VS, Poder P , Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized , placebo-controlled, double-blind study ( RUSSLAN ) [J]. Eur Heart J, 2002, 23(18) : 1 422.
  • 9苏丽军,白小涓,王标,杨光,张海山,齐国先.左西孟旦注射液治疗充血性心力衰竭的疗效评价[J].中国医科大学学报,2008,37(2):263-266. 被引量：20
  • 10岳鹏程.中西医结合治疗肺心病难治性心衰30例临床分析[J].长春中医药大学学报,2009,25(4):516-517. 被引量：8

共引文献38

同被引文献35

  • 1Kumarswamy R, Thun T. Non-coding RNAs in cardiac remodel- ing and heart failure. Circ Res, 2013,113 : 676-689.
  • 2Coons JC, McGraw M, Murali S. Pharmacotherapy for acute heart failure syndromes. Am J Health Syst Pharm, 2011,68 : 21 - 35.
  • 3Roqnoni A, Lupi A, Lazzero M, et al. Levosimendan: from ba- sic science to clinical trials. Recent Pat Cardiovasc Drug Discov, 2011,6:9-15.
  • 4鲍晓明,高希春.左西孟旦治疗急性失代偿性心力衰竭的临床疗效观察.健康必读(下旬刊),2013,3:42-43.
  • 5周海蓉,李治国.左西孟旦治疗老年重度心力衰竭的疗效及安全性观察.中国保健营养,2014,24:705-706.
  • 6Hurni C. Difficulties in diagnosis and treatment of heart failure. Ther Umsch, 2015,72 : 33-37.
  • 7Link A, Poss J, Bohm M. Pharmacotherapy of acute heart fail- ure : update and perspectives. Dtsch Med Wochenschr, 2012,137 : 126-129.
  • 8McCann P, Hauptman PJ. Inotropic therapy: an important role in the treatment of advanced symptomatic heart failure. Med Clim North Am, 2012,96: 943-954.
  • 9Pathak A, Lebrin M, Vaccaro A, et al. Pharmacology of levosi- mendan: inotropic, vasodilatory and cardio protective effects, J Clin Pharm Ther,2013,35:341-349.
  • 10Milliqan D J, Fields AM. Levosimendan: calcium sensitizer and inodilator. Anesthesiol Clin, 2010,28 : 753-760.

引证文献2

二级引证文献13

吉林医学
2015年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部